Genetic forms of epilepsies and other paroxysmal disorders

Seminars in Neurology

Volumn 34, Issue 3, 2014, Pages 266-279

  Olson, Heather E ^a,b   Poduri, Annapurna ^a,b   Pearl, Phillip L ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

chromosomal microarray; copy number variants; early onset epileptic encephalopathies; genetics; progressive myoclonus epilepsies

Indexed keywords

APHASIA; ARTICLE; CHROMOSOME ABERRATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; FAMILIAL HEMIPLEGIC MIGRAINE; FAMILY HISTORY; FOCAL EPILEPSY; GENE SEQUENCE; GENERALIZED EPILEPSY; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HAPPY PUPPET SYNDROME; HUMAN; HYPOPIGMENTATION; MENKES SYNDROME; MOTOR DYSFUNCTION; MYOCLONUS EPILEPSY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETT SYNDROME; TUBEROUS SCLEROSIS; ANIMAL; CHOREA; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HEMIPLEGIA;

ANIMALS; CHOREA; EPILEPSY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMIPLEGIA; HUMANS; PHENOTYPE;

EID: 84949122933     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1386765     Document Type: Article

References (166)

1. Shirley M. D., Tang H., Gallione C. J., et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med: 2013; 368 21 1971 1979
2. Poduri A., Evrony G. D., Cai X., Walsh C. A. Somatic mutation, genomic variation, and neurological disease. Science: 2013; 341 6141 1237758
3. Lindhout D. Somatic mosaicism as a basic epileptogenic mechanism? Brain: 2008; 131 Pt 4 900 901
4. Shi Y. W., Yu M. J., Long Y. S., et al. Mosaic SCN1A mutations in familial partial epilepsy with antecedent febrile seizures. Genes Brain Behav: 2012; 11 2 170 176
5. Bartnik M., Derwińska K., Gos M., et al. Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females. Genet Med: 2011; 13 5 447 452
6. Deprez L., Weckhuysen S., Holmgren P., et al. Clinical spectrum of early-onset epileptic encephalopathies associated with STXBP1 mutations. Neurology: 2010; 75 13 1159 1165
7. Guerrini R., Moro F., Kato M., et al. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology: 2007; 69 5 427 433
8. Olivetti P. R., Noebels J. L. Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms. Curr Opin Neurobiol: 2012; 22 5 859 865
9. Mirzaa G. M., Paciorkowski A. R., Marsh E. D., et al. CDKL5 and ARX mutations in males with early-onset epilepsy. Pediatr Neurol: 2013; 48 5 367 377
10. Saitsu H., Kato M., Mizuguchi T., et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet: 2008; 40 6 782 788
11. Mari F., Azimonti S., Bertani I., et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet: 2005; 14 14 1935 1946
12. Fehr S., Wilson M., Downs J., et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet: 2013; 21 3 266 273
13. Buiting K. Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet: 2010; 154C 3 365 376
14. Weksberg R. Imprinted genes and human disease. Am J Med Genet C Semin Med Genet: 2010; 154C 3 317 320
15. Carvill G. L., Heavin S. B., Yendle S. C., et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet: 2013; 45 7 825 830
16. Depienne C., Trouillard O., Gourfinkel-An I., et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet: 2010; 47 6 404 410
17. Gennaro E., Santorelli F. M., Bertini E., et al. Somatic and germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res Commun: 2006; 341 2 489 493
18. Scheffer I. E., Zhang Y. H., Jansen F. E., Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev: 2009; 31 5 394 400
19. Olson H. E., Poduri A.. Epilepsy: When to perform a genetic analysis. In: Miller JW, Goodkin HP, eds. Epilepsy. Hoboken, NJ: Wiley; 2014;: 159 166
20. O'Brien J. E., Meisler M. H. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. Front Genet: 2013; 4 213
21. Veeramah K. R., Johnstone L., Karafet T. M., et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia: 2013; 54 7 1270 1281
22. Martin M. S., Tang B., Papale L. A., Yu F. H., Catterall W. A., Escayg A. The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy. Hum Mol Genet: 2007; 16 23 2892 2899
23. Hawkins N. A., Martin M. S., Frankel W. N., Kearney J. A., Escayg A. Neuronal voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizures plus. Neurobiol Dis: 2011; 41 3 655 660
24. Oliva M., Berkovic S. F., Petrou S. Sodium channels and the neurobiology of epilepsy. Epilepsia: 2012; 53 11 1849 1859
25. Doty C. N. SCN9A: another sodium channel excited to play a role in human epilepsies. Clin Genet: 2010; 77 4 326 328
26. Baraban S. C., Dinday M. T., Hortopan G. A. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun: 2013; 4 2410
27. Hortopan G. A., Dinday M. T., Baraban S. C. Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech: 2010; 3 3-4 144 148
28. Liu Y., Lopez-Santiago L. F., Yuan Y., et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol: 2013; 74 1 128 139
29. Bamshad M. J., Ng S. B., Bigham A. W., et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet: 2011; 12 11 745 755
30. Allen A. S., Berkovic S. F., Cossette P., et al. Epi4K Consortium; Epilepsy Phenome/Genome Project De novo mutations in epileptic encephalopathies. Nature: 2013; 501 7466 217 221
31. Foo J. N., Liu J. J., Tan E. K. Whole-genome and whole-exome sequencing in neurological diseases. Nat Rev Neurol: 2012; 8 9 508 517
32. Handel A. E., Disanto G., Ramagopalan S. V. Next-generation sequencing in understanding complex neurological disease. Expert Rev Neurother: 2013; 13 2 215 227
33. Chu-Shore C. J., Major P., Camposano S., Muzykewicz D., Thiele E. A. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia: 2010; 51 7 1236 1241
34. Vignoli A., La Briola F., Turner K., et al. Epilepsy in TSC: certain etiology does not mean certain prognosis. Epilepsia: 2013; 54 12 2134 2142
35. Elterman R. D., Shields W. D., Mansfield K. A., Nakagawa J.; US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology: 2001; 57 8 1416 1421
36. Chiron C., Dumas C., Jambaqué I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res: 1997; 26 2 389 395
37. Krueger D. A., Wilfong A. A., Holland-Bouley K., et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol: 2013; 74 5 679 687
38. Neul J. L., Kaufmann W. E., Glaze D. G., et al. RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol: 2010; 68 6 944 950
39. Kortüm F., Das S., Flindt M., et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet: 2011; 48 6 396 406
40. Florian C., Bahi-Buisson N., Bienvenu T. FOXG1-related disorders: from clinical description to molecular genetics. Mol Syndromol: 2012; 2 3-5 153 163
41. Cardoza B., Clarke A., Wilcox J., et al. Epilepsy in Rett syndrome: association between phenotype and genotype, and implications for practice. Seizure: 2011; 20 8 646 649
42. Guerrini R., Parrini E. Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies. Epilepsia: 2012; 53 12 2067 2078
43. Pintaudi M., Calevo M. G., Vignoli A., et al. Epilepsy in Rett syndrome: clinical and genetic features. Epilepsy Behav: 2010; 19 3 296 300
44. Bao X., Downs J., Wong K., Williams S., Leonard H. Using a large international sample to investigate epilepsy in Rett syndrome. Dev Med Child Neurol: 2013; 55 6 553 558
45. Buoni S., Zannolli R., De Felice C., et al. EEG features and epilepsy in MECP2-mutated patients with the Zappella variant of Rett syndrome. Clin Neurophysiol: 2010; 121 5 652 657
46. Nissenkorn A., Gak E., Vecsler M., Reznik H., Menascu S., Ben Zeev B. Epilepsy in Rett syndrome - -the experience of a National Rett Center. Epilepsia: 2010; 51 7 1252 1258
47. Klein K. M., Yendle S. C., Harvey A. S., et al. A distinctive seizure type in patients with CDKL5 mutations: hypermotor-tonic-spasms sequence. Neurology: 2011; 76 16 1436 1438
48. Striano P., Paravidino R., Sicca F., et al. West syndrome associated with 14q12 duplications harboring FOXG1. Neurology: 2011; 76 18 1600 1602
49. Tan W. H., Bacino C. A., Skinner S. A., et al. Angelman syndrome: mutations influence features in early childhood. Am J Med Genet A: 2011; 155A 1 81 90
50. Galván-Manso M., Campistol J., Conill J., Sanmartí F. X. Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. Epileptic Disord: 2005; 7 1 19 25
51. Pelc K., Boyd S. G., Cheron G., Dan B. Epilepsy in Angelman syndrome. Seizure: 2008; 17 3 211 217
52. Thibert R. L., Larson A. M., Hsieh D. T., Raby A. R., Thiele E. A. Neurologic manifestations of Angelman syndrome. Pediatr Neurol: 2013; 48 4 271 279
53. Valente K. D., Koiffmann C. P., Fridman C., et al. Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol: 2006; 63 1 122 128
54. Vendrame M., Loddenkemper T., Zarowski M., et al. Analysis of EEG patterns and genotypes in patients with Angelman syndrome. Epilepsy Behav: 2012; 23 3 261 265
55. Zanni G., Barresi S., Cohen R., et al. A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). Epilepsy Res: 2014; 108 4 811 815
56. Olson H., Shen Y., Avallone J., et al. Copy number variation plays an important role in clinical epilepsy. Ann Neurol: 2014;; 75(6):943-958 PubMed
57. Bahi-Buisson N., Guttierrez-Delicado E., Soufflet C., et al. Spectrum of epilepsy in terminal 1p36 deletion syndrome. Epilepsia: 2008; 49 3 509 515
58. Battaglia A., Filippi T., South S. T., Carey J. C. Spectrum of epilepsy and electroencephalogram patterns in Wolf-Hirschhorn syndrome: experience with 87 patients. Dev Med Child Neurol: 2009; 51 5 373 380
59. Cordelli D. M., Garavelli L., Savasta S., et al. Epilepsy in Mowat-Wilson syndrome: delineation of the electroclinical phenotype. Am J Med Genet A: 2013; 161A 2 273 284
60. Elia M., Striano P., Fichera M., et al. 6q terminal deletion syndrome associated with a distinctive EEG and clinical pattern: a report of five cases. Epilepsia: 2006; 47 5 830 838
61. Kleefstra T., Nillesen W. M., Yntema H. G.. Kleefstra syndrome. In: Pagon RA, Adam MP, Bird TD et al, eds. GeneReviews. Seattle, WA; 1993
62. Philip N., Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. Behav Genet: 2011; 41 3 403 412
63. Sarasua S. M., Boccuto L., Sharp J. L., et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Hum Genet: 2014;; 133(7):847-859 PubMed
64. Valvo G., Novara F., Brovedani P., et al. 22q11.2 Microduplication syndrome and epilepsy with continuous spikes and waves during sleep (CSWS). A case report and review of the literature. Epilepsy Behav: 2012; 25 4 567 572
65. Heinzen E. L., Radtke R. A., Urban T. J., et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet: 2010; 86 5 707 718
66. Helbig I., Mefford H. C., Sharp A. J., et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet: 2009; 41 2 160 162
67. Mefford H. C., Muhle H., Ostertag P., et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet: 2010; 6 5 e1000962
68. de Kovel C. G., Trucks H., Helbig I., et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain: 2010; 133 Pt 1 23 32
69. Mullen S. A., Carvill G. L., Bellows S., et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology: 2013; 81 17 1507 1514
70. Specchio N., Trivisano M., Serino D., et al. Epilepsy in ring 14 chromosome syndrome. Epilepsy Behav: 2012; 25 4 585 592
71. Giovannini S., Marangio L., Fusco C., et al. Epilepsy in ring 14 syndrome: a clinical and EEG study of 22 patients. Epilepsia: 2013; 54 12 2204 2213
72. Elens I., Vanrykel K., De Waele L., et al. Ring chromosome 20 syndrome: electroclinical description of six patients and review of the literature. Epilepsy Behav: 2012; 23 4 409 414
73. Battaglia A. The inv dup (15) or idic (15) syndrome (tetrasomy 15q). Orphanet J Rare Dis: 2008; 3 30
74. Doherty M. J., Glass I. A., Bennett C. L., et al. An Xp; Yq translocation causing a novel contiguous gene syndrome in brothers with generalized epilepsy, ichthyosis, and attention deficits. Epilepsia: 2003; 44 12 1529 1535
75. Gohlke B. C., Haug K., Fukami M., et al. Interstitial deletion in Xp22.3 is associated with X linked ichthyosis, mental retardation, and epilepsy. J Med Genet: 2000; 37 8 600 602
76. van Steensel M. A., Vreeburg M., Engelen J., et al. Contiguous gene syndrome due to a maternally inherited 8.41 Mb distal deletion of chromosome band Xp22.3 in a boy with short stature, ichthyosis, epilepsy, mental retardation, cerebral cortical heterotopias and Dandy-Walker malformation. Am J Med Genet A: 2008; 146A 22 2944 2949
77. Li F., Shen Y., Köhler U., et al. Interstitial microduplication of Xp22.31: causative of intellectual disability or benign copy number variant? Eur J Med Genet: 2010; 53 2 93 99
78. Meisler M. H., Kearney J., Ottman R., Escayg A. Identification of epilepsy genes in human and mouse. Annu Rev Genet: 2001; 35 567 588
79. Helbig I., Lowenstein D. H. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol: 2013; 26 2 179 185
80. Molinari F., Kaminska A., Fiermonte G., et al. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts. Clin Genet: 2009; 76 2 188 194
81. Poduri A., Chopra S. S., Neilan E. G., et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia: 2012; 53 8 e146 e150
82. Saitsu H., Tohyama J., Kumada T., et al. Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay. Am J Hum Genet: 2010; 86 6 881 891
83. Mills P. B., Camuzeaux S. S., Footitt E. J., et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain: 2014; 137 Pt 5 1350 1360
84. Marini C., Mei D., Parmeggiani L., et al. Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology: 2010; 75 7 646 653
85. Paciorkowski A. R., Thio L. L., Dobyns W. B. Genetic and biologic classification of infantile spasms. Pediatr Neurol: 2011; 45 6 355 367
86. Barcia G., Fleming M. R., Deligniere A., et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet: 2012; 44 11 1255 1259
87. Carranza Rojo D., Hamiwka L., McMahon J. M., et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology: 2011; 77 4 380 383
88. Coppola G., Plouin P., Chiron C., Robain O., Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia: 1995; 36 10 1017 1024
89. Dhamija R., Wirrell E., Falcao G., Kirmani S., Wong-Kisiel L. C. Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy. Pediatr Neurol: 2013; 49 6 486 488
90. Freilich E. R., Jones J. M., Gaillard W. D., et al. Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy. Arch Neurol: 2011; 68 5 665 671
91. Milh M., Falace A., Villeneuve N., et al. Novel compound heterozygous mutations in TBC1D24 cause familial malignant migrating partial seizures of infancy. Hum Mutat: 2013; 34 6 869 872
92. Poduri A., Heinzen E. L., Chitsazzadeh V., et al. SLC25A22 is a novel gene for migrating partial seizures in infancy. Ann Neurol: 2013; 74 6 873 882
93. Shen J., Gilmore E. C., Marshall C. A., et al. Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet: 2010; 42 3 245 249
94. Milh M., Villeneuve N., Chouchane M., et al. Epileptic and nonepileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations. Epilepsia: 2011; 52 10 1828 1834
95. Méneret A., Gaudebout C., Riant F., Vidailhet M., Depienne C., Roze E. PRRT2 mutations and paroxysmal disorders. Eur J Neurol: 2013; 20 6 872 878
96. Pearson T. S., Akman C., Hinton V. J., Engelstad K., De Vivo D. C. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep: 2013; 13 4 342
97. Depienne C., Gourfinkel-An I., Baulac S., et al. Genes in infantile epileptic encephalopathies. In: Noebels JL, Avoli M, Rogawski MA et al, eds. Jasper's Basic Mechanisms of the Epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information; 2012
98. Mastrangelo M., Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol: 2012; 46 1 24 31
99. Dravet C., Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol: 2013; 111 627 633
100. Depienne C., Bouteiller D., Keren B., et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet: 2009; 5 2 e1000381
101. Ogiwara I., Nakayama T., Yamagata T., et al. A homozygous mutation of voltage-gated sodium channel β(I) gene SCN1B in a patient with Dravet syndrome. Epilepsia: 2012; 53 12 e200 e203
102. Patino G. A., Claes L. R., Lopez-Santiago L. F., et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci: 2009; 29 34 10764 10778
103. Harkin L. A., Bowser D. N., Dibbens L. M., et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet: 2002; 70 2 530 536
104. Carvill G. L., Weckhuysen S., McMahon J. M., et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology: 2014; 82 14 1245 1253
105. Kato M., Yamagata T., Kubota M., et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia: 2013; 54 7 1282 1287
106. Nakamura K., Kato M., Osaka H., et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology: 2013; 81 11 992 998
107. Saitsu H., Kato M., Koide A., et al. Whole exome sequencing identifies KCNQ2 mutations in Ohtahara syndrome. Ann Neurol: 2012; 72 2 298 300
108. Stockler S., Plecko B., Gospe S. M. Jr., et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab: 2011; 104 1-2 48 60
109. Touma M., Joshi M., Connolly M. C., et al. Whole genome sequencing identifies SCN2A mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings. Epilepsia: 2013; 54 5 e81 e85
110. Weckhuysen S., Ivanovic V., Hendrickx R., et al. KCNQ2 Study Group. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology: 2013; 81 19 1697 1703
111. Yu J. Y., Pearl P. L. Metabolic causes of epileptic encephalopathy. Epilepsy Res Treat: 2013; 2013 124934
112. Nicita F., De Liso P., Danti F. R., et al. The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies. Seizure: 2012; 21 1 3 11
113. Epi K. C.; Epi4K Consortium. Epi4K: gene discovery in 4,000 genomes. Epilepsia: 2012; 53 8 1457 1467
114. Mefford H. C., Yendle S. C., Hsu C., et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol: 2011; 70 6 974 985
115. Paciorkowski A. R., Thio L. L., Rosenfeld J. A., et al. Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function. Eur J Hum Genet: 2011; 19 12 1238 1245
116. Striano P., Coppola A., Paravidino R., et al. Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization. Arch Neurol: 2012; 69 3 322 330
117. Matalon D., Goldberg E., Medne L., Marsh E. D. Confirming an expanded spectrum of SCN2A mutations: a case series. Epileptic Disord: 2014; 16 1 13 18
118. Shi X., Yasumoto S., Kurahashi H., et al. Clinical spectrum of SCN2A mutations. Brain Dev: 2012; 34 7 541 545
119. Singh N. A., Westenskow P., Charlier C., et al. BFNC Physician Consortium. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain: 2003; 126 Pt 12 2726 2737
120. Orhan G., Bock M., Schepers D., et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol: 2014; 75 3 382 394
121. Chabrol B., Caillaud C., Minassian B. Neuronal ceroid lipofuscinoses. Handb Clin Neurol: 2013; 113 1701 1706
122. Ramachandran N., Girard J. M., Turnbull J., Minassian B. A. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia: 2009; 50 05 29 36
123. Girard J. M., Turnbull J., Ramachandran N., Minassian B. A. Progressive myoclonus epilepsy. Handb Clin Neurol: 2013; 113 1731 1736
124. Franceschetti S., Michelucci R., Canafoglia L., et al. Collaborative LICE study group on PMEs. Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology: 2014; 82 5 405 411
125. Delgado-Escueta A. V., Koeleman B. P., Bailey J. N., Medina M. T., Durón R. M. The quest for juvenile myoclonic epilepsy genes. Epilepsy Behav: 2013; 28 01 S52 S57
126. Taske N. L., Williamson M. P., Makoff A., et al. Evaluation of the positional candidate gene CHRNA7 at the juvenile myoclonic epilepsy locus (EJM2) on chromosome 15q13-14. Epilepsy Res: 2002; 49 2 157 172
127. Zamponi G. W., Lory P., Perez-Reyes E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch: 2010; 460 2 395 403
128. Kleefuss-Lie A., Friedl W., Cichon S., et al. CLCN2 variants in idiopathic generalized epilepsy. Nat Genet: 2009; 41 9 954 955
129. Rajakulendran S., Graves T. D., Labrum R. W., et al. Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. J Physiol: 2010; 588 Pt 11 1905 1913
130. Noebels J. L. The voltage-gated calcium channel and absence epilepsy. In: Noebels JL, Avoli M, Rogawski MA et al, eds. Jasper's Basic Mechanisms of the Epilepsies. 4th ed. Bethesda (MD); National Center for Biotechnology Information; 2012
131. Ottman R., Hirose S., Jain S., et al. Genetic testing in the epilepsies-report of the ILAE Genetics Commission. Epilepsia: 2010; 51 4 655 670
132. Heron S. E., Smith K. R., Bahlo M., et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet: 2012; 44 11 1188 1190
133. Ho Y. Y., Ionita-Laza I., Ottman R. Domain-dependent clustering and genotype-phenotype analysis of LGI1 mutations in ADPEAF. Neurology: 2012; 78 8 563 568
134. Fassio A., Patry L., Congia S., et al. SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. Hum Mol Genet: 2011; 20 12 2297 2307
135. Dibbens L. M., de Vries B., Donatello S., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet: 2013; 45 5 546 551
136. Ishida S., Picard F., Rudolf G., et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet: 2013; 45 5 552 555
137. Lal D., Reinthaler E. M., Schubert J., et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol: 2014;; 75(5):788-792
138. Martin C., Meloche C., Rioux M. F., et al. A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French-Canadian population. Clin Genet: 2013; [Epub ahead of print]
139. Scheffer I. E., Heron S. E., Regan B. M., et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol: 2014;; 75(5):782-787
140. Gregor A., Albrecht B., Bader I., et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med Genet: 2011; 12 106
141. Carvill G. L., Regan B. M., Yendle S. C., et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet: 2013; 45 9 1073 1076
142. Lemke J. R., Lal D., Reinthaler E. M., et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet: 2013; 45 9 1067 1072
143. Lesca G., Rudolf G., Bruneau N., et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet: 2013; 45 9 1061 1066
144. Endele S., Rosenberger G., Geider K., et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet: 2010; 42 11 1021 1026
145. Poretti B. Brain malformations and migrational defects. Semin Neurol: 2014; in press
146. Heinzen E. L., Swoboda K. J., Hitomi Y., et al. European Alternating Hemiplegia of Childhood (AHC) Genetics Consortium; Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC) Consortium; European Network for Research on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet: 2012; 44 9 1030 1034
147. Rosewich H., Thiele H., Ohlenbusch A., et al. Heterozygous de-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood: a whole-exome sequencing gene-identification study. Lancet Neurol: 2012; 11 9 764 773
148. Sasaki M., Ishii A., Saito Y., et al. Genotype-phenotype correlations in alternating hemiplegia of childhood. Neurology: 2014; 82 6 482 490
149. Ishii A., Saito Y., Mitsui J., et al. Identification of ATP1A3 mutations by exome sequencing as the cause of alternating hemiplegia of childhood in Japanese patients. PLoS ONE: 2013; 8 2 e56120
150. Swoboda K. J., Kanavakis E., Xaidara A., et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol: 2004; 55 6 884 887
151. Bianchin M. M., Londero R. G., Lima J. E., Bigal M. E. Migraine and epilepsy: a focus on overlapping clinical, pathophysiological, molecular, and therapeutic aspects. Curr Pain Headache Rep: 2010; 14 4 276 283
152. Silberstein S. D., Dodick D. W. Migraine genetics: Part II. Headache: 2013; 53 8 1218 1229
153. Roth C., Freilinger T., Kirovski G., et al. Clinical spectrum in three families with familial hemiplegic migraine type 2 including a novel mutation in the ATP1A2 gene. Cephalalgia: 2014; 34 3 183 190
154. Mignot C., Moutard M. L., Trouillard O., et al. STXBP1-related encephalopathy presenting as infantile spasms and generalized tremor in three patients. Epilepsia: 2011; 52 10 1820 1827
155. Scheffer I. E. Epilepsy genetics revolutionizes clinical practice. Neuropediatrics: 2014; 45 2 70 74
156. Bahi-Buisson N., Dulac O. Epilepsy in inborn errors of metabolism. Handb Clin Neurol: 2013; 111 533 541
157. Bindoff L. A., Engelsen B. A. Mitochondrial diseases and epilepsy. Epilepsia: 2012; 53 04 92 97
158. Khurana D. S., Valencia I., Goldenthal M. J., Legido A. Mitochondrial dysfunction in epilepsy. Semin Pediatr Neurol: 2013; 20 3 176 187
159. Leuzzi V., Mastrangelo M., Battini R., Cioni G. Inborn errors of creatine metabolism and epilepsy. Epilepsia: 2013; 54 2 217 227
160. Pearl P. L., Gospe S. M. Jr. Pyridoxine or pyridoxal-5′-phosphate for neonatal epilepsy: The distinction just got murkier. Neurology: 2014;; 22;82(16):1392-1394
161. van der Crabben S. N., Verhoeven-Duif N. M., Brilstra E. H., et al. An update on serine deficiency disorders. J Inherit Metab Dis: 2013; 36 4 613 619
162. Chiron C., Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia: 2011; 52 02 72 75
163. Guerrini R., Dravet C., Genton P., Belmonte A., Kaminska A., Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia: 1998; 39 5 508 512
164. Cavalleri G. L., McCormack M., Alhusaini S., Chaila E., Delanty N. Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics: 2011; 12 10 1429 1447
165. Walleigh D. J., Legido A., Valencia I. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. Pediatr Neurol: 2013; 49 5 368 369
166. Sheidley B. R., Poduri A. Genetics in clinical epilepsy: Issues in genetic testing and counseling. J Ped Epil: 2012; 1 135 142